Early Experience of Nintedanib in COVID-19 ARDS-Related Pulmonary Fibrosis: A Case Series
Vikas Marwah, Robin Choudhary, Virender Malik, Arpita Pemmaraju, Deepu Peter
Abstract
The current COVID-19 pandemic has spread like wildfire worldwide and has affected millions of people. The novel corona virus mainly affects the lungs leading to life threatening disease like acute respiratory distress syndrome (ARDS). The aftermath of the disease in form of pulmonary fibrosis is upcoming cause of further increase in morbidity and mortality. Nintedanib is an oral antifibrotics with proven role in idiopathic pulmonary fibrosis, however its use in COVID-19 related pulmonary fibrosis has not been studied. We report our early experience of use of nintedanib in COVID-19 related pulmonary fibrosis.
Topics & Concepts
NintedanibMedicineARDSPulmonary fibrosisCoronavirus disease 2019 (COVID-19)Idiopathic pulmonary fibrosisFibrosisAcute respiratory distressPandemicDiseaseIntensive care medicineInternal medicineLungInfectious disease (medical specialty)Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis